INI-4001

Phase 1Small molecule

IInimmune Corporation

INI-4001 is one of 13 small molecule programs targeting Advanced Solid Tumours. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced Solid TumoursRecruiting

Advanced Solid TumoursPhase 1

Recruiting

Competition

Competitive Landscape

22 competitors in Advanced Solid Tumours

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 2

5 2

Imfinzi

AstraZeneca

Phase 2

3 3

Vizimpro

Pfizer

Phase 2

1 4

Tuoyi

CCoherus Oncology, Inc.

Phase 2

2 5

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Phase 2

1 6

LM-108

LLaNova Medicines Limited

Phase 2

3 7

Ceralasertib

AstraZeneca

Phase 1

2 8

LM-168

LLaNova Medicines Limited

Phase 2

1 9

RC88

RRemeGen Co., Ltd.

Phase 2

2 10

FL115

SSuzhou Forlong Biotechnology Co., Ltd

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

Advanced Solid Tumours

NCT06302426

Clinical

Trials by Indication[1]

Advanced Solid Tumours1 trial

Trial of INI-4001 in Patients With Advanced Solid Tumours

Recruiting·IInimmune Corporation·Phase 1·NCT06302426·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for INI-4001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — INI-4001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for INI-4001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Inimmune Corporation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: IInimmune Corporation

INI-4001

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Advanced Solid Tumours1 trial

References

Drug Info

Quick Facts

Related News